NUVO PHARMACEUTICALS v. DR. REDDY'S LABORATORIES INC. [OPINION - NONPRECEDENTIAL] , No. 17-2487 (Fed. Cir. 2019)

Annotate this Case

Download PDF

NOTE: This disposition is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ NUVO PHARMACEUTICALS (IRELAND) DESIGNATED ACTIVITY COMPANY, HORIZON MEDICINES LLC, Plaintiffs-Appellees v. DR. REDDY'S LABORATORIES INC., DR. REDDY'S LABORATORIES, LTD., MYLAN, INC., MYLAN PHARMACEUTICALS INC., MYLAN LABORATORIES LIMITED, Defendants LUPIN LTD., LUPIN PHARMACEUTICALS, INC., Defendants-Appellants ______________________ 2017-2487, 2017-2488 ______________________ Appeals from the United States District Court for the District of New Jersey in Nos. 3:11-cv-02317-MLC-DEA, 3:11-cv-04275-MLC-DEA, Judge Mary L. Cooper. ______________________ Decided: August 7, 2019 ______________________ JAMES B. MONROE, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington, DC, argued for 2 NUVO PHARMACEUTICALS v. DR. REDDY’S LABORATORIES plaintiffs-appellees. Plaintiff-appellee Horizon Medicines LLC also represented by CHARLES COLLINS-CHASE. STEPHEN M. HASH, Baker Botts, LLP, Austin, TX, for plaintiff-appellee Nuvo Pharmaceuticals (Ireland) Designated Activity Company. Also represented by JEFFREY SEAN GRITTON. SAILESH K. PATEL, Schiff Hardin LLP, Chicago, IL, for defendants-appellants. ______________________ Before PROST, Chief Judge, CLEVENGER and WALLACH, Circuit Judges. PER CURIAM. Lupin Ltd. (Appeal No. 2017-2487) and Lupin Pharmaceuticals, Inc. (Appeal No. 2017-2488) appeal from the final judgment of the United States District Court for the District of New Jersey. Horizon Pharma, Inc. v. Lupin Ltd., No. 3:11-cv-04275-MCL-DEA (D.N.J. July 21, 2017) (final judgment). That final judgment sustained the validity of U.S. Patent Nos. 6,926,907 (“the ’907 patent”) and 8,557,285 (“the ’285 patent”), and found the appellants infringed those patents. The appellants assert that the district court erred in sustaining the validity of the ’907 and ’285 patents, and consequently erred in the judgment of infringement. The appellants are correct. In Nuvo Pharmaceuticals (Ireland) Designated Activity Company v. Dr. Reddy’s Laboratories Inc., 923 F.3d 1368 (Fed. Cir. 2019), this court held that the ’907 and ’285 patents are invalid for failure to satisfy the written description requirement in 35 U.S.C. § 112(a). The patents asserted against the appellants are invalid. The final judgment of the district court against the appellants is reversed. REVERSED NUVO PHARMACEUTICALS v. DR. REDDY'S LABORATORIES INC. COSTS No costs. 3

Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.